SCHEMBL4872156

SCHEMBL4872156

COc1nc(C(F)(F)F)cc(CO[Si](C)(C)C(C)(C)C)c1CCNC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 1/20 0.39
▸ BRD4 O60885 9/20 0.35
▸ HTT P42858 3/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ HPGD P15428 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ CACNA1H O95180 1/20 0.33
▸ CACNA1B Q00975 1/20 0.33
▸ CACNA1C Q13936 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ TRPV1 Q8NER1 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ XBP1 P17861 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864493 0.87 NQO2 (0.40) NQO2BRD4HTTNPSR1ALDH1A1
SCHEMBL14107490 0.81 CCR2 (0.39) —
SCHEMBL4867741 0.80 TAAR1 (0.35) —
SCHEMBL4792692 0.78 BACE1 (0.30) —
SCHEMBL4792743 0.78 MAPT (0.33) NPSR1HPGDALDH1A1KDM4ESMN1; SMN2
SCHEMBL4792876 0.75 POLB (0.32) —
SCHEMBL4660173 0.73 KDM4E (0.39) ALDH1A1KDM4EHSD17B10
SCHEMBL31600640 0.70 LMNA (0.41) NQO2BRD4HTTNPSR1HPGD
SCHEMBL21633558 0.68 NQO2 (0.42) NQO2HTTNPSR1HPGDALDH1A1
SCHEMBL31528049 0.68 NQO2 (0.42) NQO2HTTNPSR1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7388019-B2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK & CO., INC. (US) 2008-06-17 — — US disclosed
US-20060074087-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes MERCK SHARP & DOHME LLC 2006-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074087-A1 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes DPP4, DPP3, DPP7 NQO2 1375/4885BRD4 1446/4885HTT 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback